DK2782566T3 - L-serin til anvendelse ved behandling af neurodegenerative lidelser - Google Patents
L-serin til anvendelse ved behandling af neurodegenerative lidelser Download PDFInfo
- Publication number
- DK2782566T3 DK2782566T3 DK12851576.4T DK12851576T DK2782566T3 DK 2782566 T3 DK2782566 T3 DK 2782566T3 DK 12851576 T DK12851576 T DK 12851576T DK 2782566 T3 DK2782566 T3 DK 2782566T3
- Authority
- DK
- Denmark
- Prior art keywords
- serin
- treatment
- neurodegenerative disorders
- neurodegenerative
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161562194P | 2011-11-21 | 2011-11-21 | |
| PCT/US2012/066373 WO2013078395A1 (en) | 2011-11-21 | 2012-11-21 | L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2782566T3 true DK2782566T3 (da) | 2021-02-08 |
Family
ID=48470319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12851576.4T DK2782566T3 (da) | 2011-11-21 | 2012-11-21 | L-serin til anvendelse ved behandling af neurodegenerative lidelser |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20130156846A1 (da) |
| EP (1) | EP2782566B1 (da) |
| JP (1) | JP6265908B2 (da) |
| AU (1) | AU2012340563B2 (da) |
| CA (1) | CA2855854C (da) |
| DK (1) | DK2782566T3 (da) |
| ES (1) | ES2856063T3 (da) |
| IL (1) | IL232710B (da) |
| PT (1) | PT2782566T (da) |
| WO (1) | WO2013078395A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017535591A (ja) * | 2014-11-24 | 2017-11-30 | エントリンシック ヘルス ソリューションズ インコーポレイテッド | 疾患症状治療用アミノ酸組成物 |
| US10960076B2 (en) | 2017-01-25 | 2021-03-30 | Church & Dwight Co. Inc. | Gummy dosage forms comprising serine |
| KR20180101242A (ko) | 2017-03-02 | 2018-09-12 | 주식회사 아스트로젠 | 엘세린을 유효성분으로 포함하는 혈뇌장벽 장애의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
| WO2019237038A1 (en) * | 2018-06-08 | 2019-12-12 | The Institute For Ethnomedicine | Method of enhancing glucose levels in the central nervous system |
| KR101952443B1 (ko) * | 2018-08-23 | 2019-02-26 | 주식회사 아스트로젠 | 신규한 마그네슘세리네이트 화합물 및 이의 용도 |
| KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
| WO2021035060A1 (en) * | 2019-08-21 | 2021-02-25 | Brain Chemistry Labs | Compositions comprising a metal and l-serine, and uses thereof |
| US20220252620A1 (en) * | 2021-02-05 | 2022-08-11 | The Institute for Ethnomedicine dba Brain Chemistry Labs | Blood indicators of alzheimer's disease |
| CN112972458B (zh) * | 2021-03-05 | 2022-10-04 | 北京北科华夏生物医药科技有限公司 | 一种组合物在制备阿尔兹海默症治疗药物中的应用 |
| KR102522508B1 (ko) * | 2022-12-16 | 2023-04-18 | 주식회사 아스트로젠 | 마그네슘-세리네이트의 신규한 결정형 및 이의 제조방법 |
| WO2025014008A1 (ko) | 2023-07-07 | 2025-01-16 | 주식회사 아스트로젠 | 질환의 치료 방법 |
| KR20250081156A (ko) * | 2023-11-29 | 2025-06-05 | 주식회사 아스트로젠 | L-세린 염산염의 제조 방법 및 이의 용도 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3873722A (en) | 1974-05-31 | 1975-03-25 | Nelson Res & Dev | Method for treating schizophrenia |
| US4000318A (en) * | 1974-08-19 | 1976-12-28 | Commonwealth Scientific And Industrial Research Organization | Amino acid supplements |
| US4491589A (en) * | 1982-05-17 | 1985-01-01 | The Trustees Of Columbia University In The City Of New York | Amino acid solutions for parenteral nutrition and methods of formulation and use |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| SE8701662L (sv) * | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
| JPS6440453A (en) | 1987-08-05 | 1989-02-10 | Mitsui Toatsu Chemicals | Racemization of optically active serine |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| SE502280C2 (sv) | 1991-12-20 | 1995-09-25 | Bio Swede Ab | Separering av aminosyror, aminosyrabaserad monomer och förfarande för framställning därav samt polymert material och förfarande för framställning därav |
| WO1996015788A1 (en) | 1994-11-23 | 1996-05-30 | G.D. Searle & Co. | Use of amino-isoxazolidone compounds for improvement of implicit memory |
| CN1265588A (zh) | 1997-07-28 | 2000-09-06 | 理化学研究所 | 中枢神经细胞的保护及存活促进剂 |
| WO1999052519A2 (en) | 1998-04-14 | 1999-10-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| US6984484B1 (en) * | 1999-01-19 | 2006-01-10 | The Johns Hopkins University | Mammalian serine racemase |
| JP2002316929A (ja) * | 2001-04-18 | 2002-10-31 | Japan Science & Technology Corp | Ｌ−セリン又はグリシンからなる抗アポトーシス剤 |
| DE60331319D1 (de) * | 2002-06-19 | 2010-04-01 | Nutricia Nv | Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen |
| JP2004182705A (ja) * | 2002-10-11 | 2004-07-02 | Yasutoshi Koga | ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物 |
| US20050028720A1 (en) * | 2003-08-05 | 2005-02-10 | Bell Adam Warwick | Pop-up device for deterring an attacking animal such as a bear |
| ATE377758T1 (de) | 2003-08-12 | 2007-11-15 | Inst Ethnomedicine | Neurotoxische aminosäure oder neurotoxisches derivat davon im zusammenhang mit neurologischen störungen |
| US7148192B2 (en) | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
| FI121915B (fi) * | 2004-02-06 | 2011-06-15 | Neurofood Ab Oy | Koostumus psoriasiksen hoitoon |
| BRPI0507998A (pt) | 2004-03-26 | 2007-07-31 | Warner Lambert Co | uso de um inibidor de serina palmitoiltransferase (spt) para tratar aterosclerose e dislipidemia |
| AU2005295080A1 (en) | 2004-10-12 | 2006-04-20 | Transition Therapeutics Inc. | Compounds and methods of treating insulin resistance and cardiomyopathy |
| US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
| US20080058395A1 (en) | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| WO2008118785A2 (en) | 2007-03-23 | 2008-10-02 | Tikvah Therapeutics | Methods for treating depression using immediate-impact treatments and d-cycloserine |
| US20080241121A1 (en) | 2007-04-02 | 2008-10-02 | Daniela Salvemini | Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain |
| JP5832287B2 (ja) * | 2008-07-09 | 2015-12-16 | ジ インスティテュート フォー エスノメディスン | 神経障害に関連する神経毒性アミノ酸を検出するためのイムノアッセイ |
| US9072730B2 (en) * | 2009-05-14 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease |
| WO2011104298A1 (en) * | 2010-02-24 | 2011-09-01 | Universität Zürich | Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids |
-
2012
- 2012-11-21 DK DK12851576.4T patent/DK2782566T3/da active
- 2012-11-21 ES ES12851576T patent/ES2856063T3/es active Active
- 2012-11-21 CA CA2855854A patent/CA2855854C/en active Active
- 2012-11-21 WO PCT/US2012/066373 patent/WO2013078395A1/en not_active Ceased
- 2012-11-21 PT PT128515764T patent/PT2782566T/pt unknown
- 2012-11-21 AU AU2012340563A patent/AU2012340563B2/en active Active
- 2012-11-21 US US13/683,821 patent/US20130156846A1/en not_active Abandoned
- 2012-11-21 JP JP2014543579A patent/JP6265908B2/ja active Active
- 2012-11-21 EP EP12851576.4A patent/EP2782566B1/en active Active
-
2014
- 2014-03-28 US US14/229,624 patent/US11917986B2/en active Active
- 2014-05-20 IL IL232710A patent/IL232710B/en unknown
-
2017
- 2017-10-06 US US15/727,335 patent/US11700840B2/en active Active
-
2021
- 2021-02-02 US US17/165,897 patent/US12295353B2/en active Active
- 2021-07-12 US US17/373,434 patent/US11974551B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL232710B (en) | 2021-12-01 |
| AU2012340563B2 (en) | 2017-01-19 |
| US20220000082A1 (en) | 2022-01-06 |
| US20180027781A1 (en) | 2018-02-01 |
| IL232710A0 (en) | 2014-07-31 |
| ES2856063T3 (es) | 2021-09-27 |
| EP2782566A4 (en) | 2016-01-13 |
| US11974551B2 (en) | 2024-05-07 |
| EP2782566A1 (en) | 2014-10-01 |
| JP6265908B2 (ja) | 2018-01-24 |
| CA2855854A1 (en) | 2013-05-30 |
| US20140212893A1 (en) | 2014-07-31 |
| PT2782566T (pt) | 2021-03-03 |
| JP2014534263A (ja) | 2014-12-18 |
| AU2012340563A1 (en) | 2014-05-29 |
| US11700840B2 (en) | 2023-07-18 |
| EP2782566B1 (en) | 2021-01-06 |
| WO2013078395A1 (en) | 2013-05-30 |
| CA2855854C (en) | 2020-03-31 |
| US20130156846A1 (en) | 2013-06-20 |
| US12295353B2 (en) | 2025-05-13 |
| US20210153483A1 (en) | 2021-05-27 |
| US11917986B2 (en) | 2024-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281178A (en) | Methods of treating or preventing cholesterol related disorders | |
| DK2782566T3 (da) | L-serin til anvendelse ved behandling af neurodegenerative lidelser | |
| HUE043171T2 (hu) | Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK3321276T3 (da) | Fusionsproteiner til behandling af metaboliske lidelser | |
| DK3305317T3 (da) | Forbindelser til behandling af neuropsykiatriske forstyrrelser | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| DK2938740T3 (da) | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| DK2900061T3 (da) | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling | |
| DK2830662T3 (da) | Fremgangsmåder til behandlng af hårtabsforstyrrelser | |
| DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
| EP2873047A4 (en) | APPROVAL OF TRANSACTIONS | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| PL2838539T3 (pl) | Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych | |
| DK3581199T3 (da) | Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis | |
| BR112014004416A2 (pt) | composições e métodos para o tratamento de doenças neurodegenerativas | |
| DK2822558T3 (da) | Procaspase 3 aktivering ved hjælp af kombinations terapi | |
| DK2522342T3 (da) | Topisk formulering til behandling af hyperkeratonisk hud | |
| DK2838907T3 (da) | Aminosteroider til behandlingen af en ptp1b-associeret sygdom | |
| HUE046508T2 (hu) | Orvepitant krónikus viszketés kezelésére | |
| DK2807170T3 (da) | Phragmalin-limonoider til behandlingen af seksuel dysfunktion | |
| IL227747A0 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| DK2701707T3 (da) | Fremgangsmåde til behandling af dyskinesi | |
| DK2705847T3 (da) | Sammensætning til behandling af psoriasis |